Clinical research organisation (CRO), Celerion, has been the recipient of a CRO Leadership Award for the fourth time. It was awarded the honour by global biopharmaceutical executives at the Life Science Leader’s annual CRO Leadership Awards for 2017.
Award
The awards are based on research from the Industry Standard Research’s Contract Research Organization Quality Benchmarking annual online survey. In this survey, 72 CROs were evaluated on 27 different performance metrics.
Awards are separated into three groups, Big Pharma, Small Pharma and Overall (a combination of big and small pharma). Within each group there are five categories comprising capabilities, compatibility, expertise, quality and reliability. Celerion was acknowledged as a leader in all five categories.
“We would like to thank our clients for this recognition and their continued partnership with Celerion,” stated Susan Thornton, president and CEO of Celerion. “For over 40 years, Celerion has been at the forefront of early clinical research. Winning the CRO Leadership award highlights the value we consistently deliver to our clients. Our extensive experience and expertise in managing complex early phase studies in healthy volunteers and patients enables us to provide unique insights for successful clinical development programmes.”